179 related articles for article (PubMed ID: 34093963)
1. The protective effect of olanzapine on ketamine induced cognitive deficit and increased NR1 expression in rat model of schizophrenia.
Mahmoud GS; Hosny G; Sayed SA
Int J Physiol Pathophysiol Pharmacol; 2021; 13(2):22-35. PubMed ID: 34093963
[TBL] [Abstract][Full Text] [Related]
2. Effect of clozapine on ketamine-induced deficits in attentional set shift task in mice.
Szlachta M; Pabian P; Kuśmider M; Solich J; Kolasa M; Żurawek D; Dziedzicka-Wasylewska M; Faron-Górecka A
Psychopharmacology (Berl); 2017 Jul; 234(14):2103-2112. PubMed ID: 28405711
[TBL] [Abstract][Full Text] [Related]
3. Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine.
de Araújo FYR; Chaves Filho AJM; Nunes AM; de Oliveira GV; Gomes PXL; Vasconcelos GS; Carletti J; de Moraes MO; de Moraes ME; Vasconcelos SMM; de Sousa FCF; de Lucena DF; Macedo DS
Metab Brain Dis; 2021 Dec; 36(8):2283-2297. PubMed ID: 34491479
[TBL] [Abstract][Full Text] [Related]
4. Standardized extract of Erythrina velutina Willd. attenuates schizophrenia-Like behaviours and oxidative parameters in experimental animal models.
Dias KCF; de Almeida JC; Vasconcelos LC; Patrocínio MLV; Barbosa TM; Ximenes NC; Leitão APA; Louchard BO; Pimenta ATÁ; Pinto FDCL; Leal LKAM; Honório Junior JER; Vasconcelos SMM
J Pharm Pharmacol; 2019 Mar; 71(3):379-389. PubMed ID: 30456833
[TBL] [Abstract][Full Text] [Related]
5. Brain Sub/Region-Specific Effects of Olanzapine on c-Fos Expression of Chronically Socially Isolated Rats.
Stanisavljević A; Perić I; Gass P; Inta D; Lang UE; Borgwardt S; Filipović D
Neuroscience; 2019 Jan; 396():46-65. PubMed ID: 30458222
[TBL] [Abstract][Full Text] [Related]
6. Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats.
Kozela E; Krawczyk M; Kos T; Juknat A; Vogel Z; Popik P
Mol Neurobiol; 2020 Mar; 57(3):1733-1747. PubMed ID: 31823199
[TBL] [Abstract][Full Text] [Related]
7. The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice.
Kos T; Nikiforuk A; Rafa D; Popik P
Psychopharmacology (Berl); 2011 Apr; 214(4):911-21. PubMed ID: 21161188
[TBL] [Abstract][Full Text] [Related]
8. Cannabidiol Modulates the Motor Profile and NMDA Receptor-related Alterations Induced by Ketamine.
Brakatselos C; Delis F; Asprogerakas MZ; Lekkas P; Tseti I; Tzimas PS; Petrakis EA; Halabalaki M; Skaltsounis LA; Antoniou K
Neuroscience; 2021 Feb; 454():105-115. PubMed ID: 32950556
[TBL] [Abstract][Full Text] [Related]
9. The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning.
Song WS; Cha JH; Yoon SH; Cho YS; Park KY; Kim MH
Neuropharmacology; 2017 Mar; 114():1-11. PubMed ID: 27866902
[TBL] [Abstract][Full Text] [Related]
10. Involvement of GABAergic, BDNF and Nox-2 mechanisms in the prevention and reversal of ketamine-induced schizophrenia-like behavior by morin in mice.
Ben-Azu B; Aderibigbe AO; Ajayi AM; Eneni AO; Umukoro S; Iwalewa EO
Brain Res Bull; 2018 May; 139():292-306. PubMed ID: 29548911
[TBL] [Abstract][Full Text] [Related]
11. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia.
Becker A; Peters B; Schroeder H; Mann T; Huether G; Grecksch G
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):687-700. PubMed ID: 12787858
[TBL] [Abstract][Full Text] [Related]
12. Long-term potentiation prevents ketamine-induced aberrant neurophysiological dynamics in the hippocampus-prefrontal cortex pathway in vivo.
Lopes-Aguiar C; Ruggiero RN; Rossignoli MT; Esteves IM; Peixoto-Santos JE; Romcy-Pereira RN; Leite JP
Sci Rep; 2020 Apr; 10(1):7167. PubMed ID: 32346044
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.
Mohammed A; El-Bakly WM; Ali A; El-Demerdash E
Behav Brain Res; 2020 Jan; 378():112305. PubMed ID: 31634496
[TBL] [Abstract][Full Text] [Related]
14. Parvalbumin Loss Following Chronic Sub-Anesthetic NMDA Antagonist Treatment is Age-Dependent in the Hippocampus: Implications for Modeling NMDA Hypofunction.
Honeycutt JA; Chrobak JJ
Neuroscience; 2018 Nov; 393():73-82. PubMed ID: 30296474
[TBL] [Abstract][Full Text] [Related]
15. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.
Vasconcelos GS; Ximenes NC; de Sousa CN; Oliveira Tde Q; Lima LL; de Lucena DF; Gama CS; Macêdo D; Vasconcelos SM
Schizophr Res; 2015 Jul; 165(2-3):163-70. PubMed ID: 25937462
[TBL] [Abstract][Full Text] [Related]
16. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Zhang C; Fang Y; Xu L
Schizophr Res; 2014 Nov; 159(2-3):376-84. PubMed ID: 25219486
[TBL] [Abstract][Full Text] [Related]
17. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats.
Nikiforuk A; Gołembiowska K; Popik P
Eur Neuropsychopharmacol; 2010 Jan; 20(1):37-48. PubMed ID: 19729284
[TBL] [Abstract][Full Text] [Related]
18. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
[TBL] [Abstract][Full Text] [Related]
19. The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.
Bilgic S; Tastemir Korkmaz D; Azirak S; Guvenc AN; Kocaman N; Ozer MK
Bratisl Lek Listy; 2017; 118(10):618-625. PubMed ID: 29198130
[TBL] [Abstract][Full Text] [Related]
20. The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model.
Martínez-Pinteño A; García-Cerro S; Mas S; Torres T; Boloc D; Rodríguez N; Lafuente A; Gassó P; Arnaiz JA; Parellada E
J Psychiatr Res; 2020 Jul; 126():8-18. PubMed ID: 32407891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
